Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC.
Takeoka T, Nagase H, Kurose K, Ohue Y, Yamasaki M, Takiguchi S, Sato E, Isobe M, Kanazawa T, Matsumoto M, Iwahori K, Kawashima A, Morimoto-Okazawa A, Nishikawa H, Oka M, Pan L, Venhaus R, Nakayama E, Mori M, Doki Y, Wada H. Takeoka T, et al. J Immunother. 2017 May;40(4):140-147. doi: 10.1097/CJI.0000000000000162. J Immunother. 2017. PMID: 28338507
Immunological classification of renal cell carcinoma patients based on phenotypic analysis of immune check-point molecules.
Kawashima A, Kanazawa T, Goto K, Matsumoto M, Morimoto-Okazawa A, Iwahori K, Ujike T, Nagahara A, Fujita K, Uemura M, Nonomura N, Wada H. Kawashima A, et al. Among authors: morimoto okazawa a. Cancer Immunol Immunother. 2018 Jan;67(1):113-125. doi: 10.1007/s00262-017-2060-5. Epub 2017 Oct 3. Cancer Immunol Immunother. 2018. PMID: 28975380 Free PMC article.
Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients.
Kato R, Yamasaki M, Urakawa S, Nishida K, Makino T, Morimoto-Okazawa A, Kawashima A, Iwahori K, Suzuki S, Ueda R, Mori M, Satoh T, Doki Y, Wada H. Kato R, et al. Among authors: morimoto okazawa a. Cancer Immunol Immunother. 2018 Nov;67(11):1673-1683. doi: 10.1007/s00262-018-2225-x. Epub 2018 Aug 20. Cancer Immunol Immunother. 2018. PMID: 30128737 Free PMC article. Clinical Trial.
Peri-operative monocyte count is a marker of poor prognosis in gastric cancer: increased monocytes are a characteristic of myeloid-derived suppressor cells.
Urakawa S, Yamasaki M, Goto K, Haruna M, Hirata M, Morimoto-Okazawa A, Kawashima A, Iwahori K, Makino T, Kurokawa Y, Yamada T, Mori M, Doki Y, Wada H. Urakawa S, et al. Among authors: morimoto okazawa a. Cancer Immunol Immunother. 2019 Aug;68(8):1341-1350. doi: 10.1007/s00262-019-02366-0. Epub 2019 Jul 19. Cancer Immunol Immunother. 2019. PMID: 31324947 Free PMC article.
The impact of ICOS+ regulatory T cells and Helicobacter pylori infection on the prognosis of patients with gastric and colorectal cancer: potential prognostic benefit of pre-operative eradication therapy.
Urakawa S, Yamasaki M, Makino T, Kurokawa Y, Yamamoto K, Goto K, Haruna M, Hirata M, Morimoto-Okazawa A, Kawashima A, Iwahori K, Mizushima T, Sato E, Mori M, Doki Y, Wada H. Urakawa S, et al. Among authors: morimoto okazawa a. Cancer Immunol Immunother. 2021 Feb;70(2):443-452. doi: 10.1007/s00262-020-02696-4. Epub 2020 Aug 16. Cancer Immunol Immunother. 2021. PMID: 32803278 Free PMC article.
Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma.
Nishida K, Kawashima A, Kanazawa T, Kidani Y, Yoshida T, Hirata M, Yamamoto K, Yamamoto Y, Sawada M, Kato R, Kato T, Hatano K, Ujike T, Fujita K, Uemura M, Morimoto-Okazawa A, Iwahori K, Yamasaki M, Ohkura N, Sakaguchi S, Nonomura N, Doki Y, Wada H. Nishida K, et al. Among authors: morimoto okazawa a. Int Immunol. 2020 May 8;32(5):347-357. doi: 10.1093/intimm/dxaa004. Int Immunol. 2020. PMID: 31950169
Phenotypic Analysis of Tumor Tissue-Infiltrating Lymphocytes in Tumor Microenvironment of Bladder Cancer and Upper Urinary Tract Carcinoma.
Kawashima A, Kanazawa T, Jingushi K, Kato T, Ujike T, Nagahara A, Fujita K, Morimoto-Okazawa A, Iwahori K, Uemura M, Imamura R, Wada H, Nonomura N. Kawashima A, et al. Among authors: morimoto okazawa a. Clin Genitourin Cancer. 2019 Apr;17(2):114-124. doi: 10.1016/j.clgc.2018.11.004. Epub 2018 Nov 17. Clin Genitourin Cancer. 2019. PMID: 30555025
Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment.
Iwahori K, Shintani Y, Funaki S, Yamamoto Y, Matsumoto M, Yoshida T, Morimoto-Okazawa A, Kawashima A, Sato E, Gottschalk S, Okumura M, Kumanogoh A, Wada H. Iwahori K, et al. Among authors: morimoto okazawa a. Sci Rep. 2019 Feb 22;9(1):2636. doi: 10.1038/s41598-019-39345-5. Sci Rep. 2019. PMID: 30796310 Free PMC article.
Docetaxel Upregulates HMGB1 Levels in Non-small Cell Lung Cancer.
Haruna M, Hirata M, Iwahori K, Kanazawa T, Yamamoto Y, Goto K, Kawashima A, Morimoto-Okazawa A, Funaki S, Shintani Y, Kumanogoh A, Wada H. Haruna M, et al. Among authors: morimoto okazawa a. Biol Pharm Bull. 2020;43(3):399-403. doi: 10.1248/bpb.b19-00702. Biol Pharm Bull. 2020. PMID: 32115500 Free article.
12 results